LDX Stock Overview
A contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lumos Diagnostics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.046 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.01 |
| Beta | 0.74 |
| 1 Month Change | -19.30% |
| 3 Month Change | -41.77% |
| 1 Year Change | 206.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.49% |
Recent News & Updates
Recent updates
Take Care Before Diving Into The Deep End On Lumos Diagnostics Holdings Limited (ASX:LDX)
Jan 03
The Market Lifts Lumos Diagnostics Holdings Limited (ASX:LDX) Shares 387% But It Can Do More
Jul 04Bearish: Analysts Just Cut Their Lumos Diagnostics Holdings Limited (ASX:LDX) Revenue and EPS estimates
Jul 12Shareholder Returns
| LDX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -8.0% | 2.2% | 0.7% |
| 1Y | 206.7% | 18.2% | 7.8% |
Return vs Industry: LDX exceeded the Australian Medical Equipment industry which returned 18.2% over the past year.
Return vs Market: LDX exceeded the Australian Market which returned 7.8% over the past year.
Price Volatility
| LDX volatility | |
|---|---|
| LDX Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 9.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: LDX's share price has been volatile over the past 3 months.
Volatility Over Time: LDX's weekly volatility has decreased from 83% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Doug Ward | lumosdiagnostics.com |
Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company’s products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers.
Lumos Diagnostics Holdings Limited Fundamentals Summary
| LDX fundamental statistics | |
|---|---|
| Market cap | AU$22.14m |
| Earnings (TTM) | -AU$13.17m |
| Revenue (TTM) | AU$12.27m |
1.8x
P/S Ratio-1.7x
P/E RatioIs LDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDX income statement (TTM) | |
|---|---|
| Revenue | US$8.21m |
| Cost of Revenue | US$3.81m |
| Gross Profit | US$4.41m |
| Other Expenses | US$13.23m |
| Earnings | -US$8.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 53.64% |
| Net Profit Margin | -107.38% |
| Debt/Equity Ratio | 0% |
How did LDX perform over the long term?
See historical performance and comparison